BarrySZingmanMD

HIV/AIDS Medicine

Professor, Medicine, Infectious Diseases, Albert Einstein College of Medicine

Dr. Zingman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
111 E 210th St
AIDS Center
Bronx, NY 10467
Phone+1 718-920-2647

Fax+1 718-405-0610

PubMed

118 citations
HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%.
Jonathan Shuter, Julie A Sarlo, Tina J. Kanmaz, Richard A. Rode, Barry S. Zingman
Journal of Acquired Immune Deficiency Syndromes. 2007-05-01
1882 citations
Remdesivir for the Treatment of Covid-19 - Final Report.
John H Beigel, Kay M Tomashek, Lori E Dodd, Aneesh K Mehta, Barry S Zingman
The New England Journal of Medicine. 2020-11-05
72 citations
Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults
Jeffrey M. Jacobson, Jacob Lalezari, Melanie A. Thompson, Carl J. Fichtenbaum, Michael S. Saag
Antimicrobial Agents and Chemotherapy. 2010-10-01

Journal Articles

Remdesivir for the Treatment of Covid-19 — Final Report
Aneesh K Mehta, Barry S Zingman, Andre C Kalil, Helen Y Chu, Robert W Finberg, Kerry Dierberg, Victor Tapson, Lanny Hsieh, Thomas F Patterson, Daniel A Sweeney, Willia..., The New England Journal of Medicine

Montefiore AIDS Center Awarded $1 Million to Curb Disproportionate Impact of HIV on Women of Color in the BronxOctober 8th, 2024
Resverlogix Announces Type C Meeting with FDA for CORAL, a Phase 3 High-Risk COVID-19 Outpatient StudyMay 9th, 2022
Montefiore/Einstein Lead Drug Trial on COVID-19 Antiviral Drug, Merck, Approved in the UKNovember 8th, 2021
Join now to see all